Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging
Reference36 articles.
1. Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, et al. Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017;Volume 11:2643–51.
https://doi.org/10.2147/DDDT.S122417
.
2. ClinicalTrials.gov n.d.
https://clinicaltrials.gov/
. Accessed 30 Sept 2018.
3. Flux GD. Imaging and dosimetry for radium-223: the potential for personalized treatment. Br J Radiol. 2017.
https://doi.org/10.1259/bjr.20160748
.
4. Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8:587–94.
https://doi.org/10.1016/S1470-2045(07)70147-X
.
5. Liepe K. Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr Opin Investig Drugs. 2009;10:1346–58.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献